Abbott ABTrecently announced results for its AMPLATZER Amulet left atrial appendage (LAA) occlusion device in a bid to fortify its core Structural Heart business. Data was presented at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in Paris.
Further, these results were published in EuroIntervention.Abbott Presents Positive Data for AMPLATZER Amulet Device
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться